2026-05-28T12:19:46Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/146292026-02-03T10:54:17Zcom_10630_2254col_10630_37953

00925njm 22002777a 4500 dc Fernández-Rovira, Alicia author Lavado Valenzuela, Rocío author Berciano-Guerrero, Miguel Ángel author Navas-Delgado, Ismael author Aldana-Montes, José Francisco author 2017-09-26 Melanoma is a highly immunogenic tumor. Therefore, in recent years physicians have incorporated drugs that alter the immune system into their therapeutic arsenal against this disease, revolutionizing in the treatment of patients in an advanced stage of the disease. This has led us to explore and deepen our knowledge of the immunology surrounding melanoma, in order to optimize its approach. At present, immunotherapy for metastatic melanoma is based on stimulating an individual’s own immune system through the use of specific monoclonal antibodies. The use of immunotherapy has meant that many of patients with melanoma have survived and therefore it constitutes a present and future treatment in this field. At the same time, drugs have been developed targeting specific mutations, specifically BRAF, resulting in large responses in tumor regression (set up in this clinical study to 18 months), as well as a higher percentage of long-term survivors. The analysis of the gene expression changes and their correlation with clinical changes can be developed using the tools provided by those companies which currently provide gene expression platforms. The gene expression platform used in this clinical study is NanoString, which provides nCounter. However, nCounter has some limitations as the type of analysis is restricted to a predefined set, and the introduction of clinical features is a complex task. This paper presents an approach to collect the clinical information using a structured database and a Web user interface to introduce this information, including the results of the gene expression measurements, to go a step further than the nCounter tool. As part of this work, we present an initial analysis of changes in the gene expression of a set of patients before and after targeted therapy. This analysis has been carried out using Big Data technologies (Apache Spark) with the final goal being to scale up to large numbers of patients, even though this initial study has a limited number of enrolled patients (12 in the first analysis). This is not a Big Data problem, but the underlaying study aims at targeting 20 patients per year just in Málaga, and this could be extended to be used to analyze the 3.600 patients diagnosed with melanoma per year. Fernandez-Rovira A, Lavado-Valenzuela R, Berciano Guerrero MÁ, Navas-Delgado I, Aldana-Montes JF. (2017) Melanoma expression analysis with Big Data technologies. PeerJ Preprints 5:e3260v2 https://doi.org/10.7287/peerj.preprints.3260v2 http://hdl.handle.net/10630/14629 http://orcid.org/0000-0001-7819-5416 Cancer - Proceso de datos - Congresos Melanoma expression analysis with Big Data technologies